SCHEMBL3574508

SCHEMBL3574508

O=C(C=Cc1c(F)cccc1F)C=Cc1c(F)cccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.59
KRAS P01116 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HPGD P15428 4/20 0.49
LMNA P02545 2/20 0.49
ALOX12 P18054 1/20 0.49
ATM Q13315 1/20 0.49
NFE2L2 Q16236 2/20 0.48
HSD11B1 P28845 1/20 0.48
MAPT P10636 2/20 0.47
MDM4 O15151 1/20 0.47
MDM2 Q00987 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
PLIN1 O60240 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP2D6 P10635 1/20 0.46
F3 P13726 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574506 1.00 ABCG2 (0.59) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL979804 0.86 SMN1; SMN2 (0.67) ABCG2SMN1; SMN2HPGDLMNAALOX12
SCHEMBL979806 0.86 SMN1; SMN2 (0.67) ABCG2SMN1; SMN2HPGDLMNAALOX12
SCHEMBL1226435 0.84 ABCG2 (0.58) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL1226433 0.84 ABCG2 (0.58) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL5750500 0.83 ABCG2 (0.56) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL2907919 0.83 ABCG2 (0.56) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL2907918 0.83 ABCG2 (0.56) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL167101 0.83 ABCG2 (0.56) ABCG2KRASSMN1; SMN2HPGDLMNA
SCHEMBL5750497 0.83 ABCG2 (0.56) ABCG2KRASSMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842705-B2 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY (US) 2010-11-30 US disclosed
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES EMORY UNIVERSITY 2008-09-25 US disclosed
US-6664272-B2 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue EMORY UNIVERSITY 2003-12-16 US disclosed
EP-1242379-A1 CURCUMIN ANALOGUES FOR TREATING CANCER Emory University (US) 2002-09-25 EP disclosed
WO-2001040188-A9 CURCUMIN ANALOGUES FOR TREATING CANCER UNIV EMORY (US) 2002-07-25 WO disclosed
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties EMORY UNIVERSITY 2002-02-14 US disclosed
WO-2001040188-A1 CURCUMIN ANALOGUES FOR TREATING CANCER EMORY UNIVERSITY (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234320-A1 CURCUMIN ANALOGS WITH ANTI-TUMOR AND ANTI-ANGIOGENIC PROPERTIES PGF, VEGFA, VHL ABCG2 175/4885KRAS 657/4885SMN1; SMN2 4361/4885
US-20020019382-A1 Curcumin analogs with anti-tumor and anti-angiogenic properties PGF, VEGFA, VHL ABCG2 175/4885KRAS 657/4885SMN1; SMN2 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.